Genetic Technologies: New Risk Assessment Tests for Cancer

Facebooktwitterlinkedinmail

Genetic Technologies: New Risk Assessment Tests for Cancer

Exclusive interview with Dr. Jerzy Mechnicki , interim-CEO of Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE), a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products.

Facebooktwitterlinkedinmail